Clinical Trials Logo

Clinical Trial Summary

This is a single-armed, open-labeled and single-centered study of everolimus in selective patients with metastatic melanoma for evaluation of the efficacy and safety. The study objective is to evaluate efficacy profile of everolimus.

The patients who comply with the inclusion and exclusion criteria will be enrolled. The estimated recruiting duration is 18 months. Everolimus will be given in the dose of 10 mg orally each day at lease 6 months unless disease progression or intolerance. The follow-up is till death(at least 1 year).

Clinical Trial Description


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

NCT number NCT01960829
Study type Interventional
Source Beijing Cancer Hospital
Contact Lu Si, MD
Phone 0086018819
Status Recruiting
Phase Phase 2
Start date September 2013

See also
  Status Clinical Trial Phase
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Recruiting NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Recruiting NCT02854488 - Yervoy Pregnancy Surveillance Study N/A
Recruiting NCT03620019 - Denosumab + Pembrolizumab in Patients With Stage IV Melanoma Phase 2
Recruiting NCT03683550 - Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in Melanoma N/A
Active, not recruiting NCT01667419 - A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma Phase 3
Not yet recruiting NCT03224208 - Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients Phase 2
Recruiting NCT02760225 - Pembrolizumab-PET Imaging N/A
Recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Recruiting NCT02890368 - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Phase 1
Recruiting NCT02909348 - Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab N/A
Terminated NCT02796352 - A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study Phase 2
Recruiting NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Active, not recruiting NCT02574377 - myDC/pDC in Stage III Melanoma Patients Phase 1/Phase 2
Recruiting NCT02143050 - Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients Phase 1/Phase 2
Active, not recruiting NCT02251314 - Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma N/A
Active, not recruiting NCT01909453 - Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Phase 3
Active, not recruiting NCT01941927 - Trametinib With GSK2141795 in BRAF Wild-type Melanoma Phase 2
Terminated NCT01942993 - The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma Phase 2